After resolving FCPA violations in 2016, GSK reports new problem to US
The pharmaceutical company has alerted US authorities to an inquiry into third-party advisers that it engaged during the course of a bribery investigation in China.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10